Milestone Pharmaceuticals (MIST) Stock Price, Quote, News & History | Benzinga

Milestone Pharmaceuticals Inc (MIST) Stock Price, Quote, News & History

MISTNASDAQ

Trade with Public

Trade with Public

$1.15

-0.01-0.86%

Last update: Aug 26, 1:22 PM

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Compare Options Stock Report

Key Statistics

Open

$1.17

Close

-

Volume / Avg.

447.98K / 1.43M

Day Range

$1.13 - $1.19

52 Wk Range

1.00 - 3.06

Market Cap

$143.17M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

50

Short Interest

13.46%

Days to Cover

9.4

Recent Milestone Pharmaceuticals Inc News

This Sphere Entertainment Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday

Top Wall Street analysts updated ratings on SPHR, CVLG, MIST, MSGE,. Check out analyst ratings page for full details and stock recommendations.

Avi Kapoor

Milestone Reports Q1 Results, Highlights Initial CARDAMYST Sales

Milestone Pharmaceuticals Inc. (NASDAQ: MIST) reported first-quarter earnings on Wednesday before the market opened.

Dylan Berman

Why Milestone Pharma Stock Is Taking A Dive Today

EU decision delay for Milestone Pharmaceuticals etripamil, despite strong U.S. launch progress, solid sales beat and cash runway into 2027.

Vandana Singh

Milestone Pharmaceuticals Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

Earnings report for Milestone Pharmaceuticals Inc. (MIST) expected on March 19. Analysts predict 16 cents per share on $1.20M revenue.

Avi Kapoor

Milestone Wins FDA Approval For First Self-Use Nasal Spray For Sudden Fast Heartbeats

The FDA approved Milestone Pharmaceuticals' Cardamyst nasal spray for acute episodes of PSVT in adults. First treatment for PSVT in 30 years.

Vandana Singh

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-61.29M

Investing Cash Flow (TTM)

-319.00K

Financing Cash Flow (TTM)

188.84M

Free Cash Flow (TTM)

-61.65M

Capital Expenditure (TTM)

-356.00K

Net Change in Cash (TTM)

127.23M

Analyst Trends and Forecast

1

May

1

Aug

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.3

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$33.88M

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

58.41

PB Ratio (TTM)

7.93

Earnings Yield % (TTM)

-56.03%

Earnings Yield % (FWD)

-74.14%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$0.15

Company Debt

Total Debt

$59.21M

LT Debt

$59.21M

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-

Total Cash

$169.73M

Debt to Equity

3.30

Issuance of Debt (TTM)

-

Repayment of Debt (TTM)

-

Key Statistics

Open

$1.17

Close

-

Volume / Avg.

447.98K / 1.43M

Day Range

$1.13 - $1.19

52 Wk Range

1.00 - 3.06

Market Cap

$143.17M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

50

Short Interest

13.46%

Days to Cover

9.4

About

Sector

Health Care

Industry

Pharmaceuticals

Milestone Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of cardiovascular medicines. Its approved product CARDAMYST (etripamil) nasal spray is available in the United States and is the self-admini...

Show More

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

Q

How do I buy Milestone Pharmaceuticals (MIST) stock?

A

You can purchase shares of Milestone Pharmaceuticals (NASDAQ:MIST) through any online brokerage.

View our list of the best stock brokerages

Q

Who are Milestone Pharmaceuticals (MIST) competitors?

A

Other companies in Milestone Pharmaceuticals’s space includes: Eli Lilly and Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), Merck & Co Inc (NYSE:MRK), Novartis AG (NYSE:NVS) and AstraZeneca PLC (NYSE:AZN).

Q

What is the forecast, or price target, for Milestone Pharmaceuticals (MIST) stock?

A

Milestone Pharmaceuticals has a consensus price target of $7.38.

Q

What is the current price for Milestone Pharmaceuticals (MIST)?

A

The stock price for Milestone Pharmaceuticals (NASDAQ: MIST) is $1.15 last updated August 26, 2026 at 1:22 PM EDT.

Q

Does Milestone Pharmaceuticals (MIST) pay a dividend?

A

There are no upcoming dividends for Milestone Pharmaceuticals.

Q

When is Milestone Pharmaceuticals (NASDAQ:MIST) reporting earnings?

A

Milestone Pharmaceuticals does not have any upcoming earnings scheduled.

Q

Is Milestone Pharmaceuticals (MIST) going to split?

A

There is no upcoming split for Milestone Pharmaceuticals.

Q

What sector and industry does Milestone Pharmaceuticals (MIST) operate in?

A

Milestone Pharmaceuticals is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.